Combinatorial Strategies for the Induction of Immunogenic Cell Death
Top Cited Papers
Open Access
- 24 April 2015
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 6, 187
- https://doi.org/10.3389/fimmu.2015.00187
Abstract
The term “immunogenic cell death” (ICD) is commonly employed to indicate a peculiar instance of regulated cell death (RCD) that engages the adaptive arm of the immune system. The inoculation of cancer cells undergoing ICD into immunocompetent animals elicits a specific immune response associated with the establishment of immunological memory. Only a few agents are intrinsically endowed with the ability to trigger ICD. These include a few chemotherapeutics that are routinely employed in the clinic, like doxorubicin, mitoxantrone, oxaliplatin, and cyclophosphamide, as well as some agents that have not yet been approved for use in humans. Accumulating clinical data indicate that the activation of adaptive immune responses against dying cancer cells is associated with improved disease outcome in patients affected by various neoplasms. Thus, novel therapeutic regimens that trigger ICD are urgently awaited. Here, we discuss current combinatorial approaches to convert otherwise non-immunogenic instances of RCD into bona fide ICD.This publication has 139 references indexed in Scilit:
- Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T CellsPLOS ONE, 2013
- The Hallmarks of AgingCell, 2013
- Many faces of DAMPs in cancer therapyCell Death & Disease, 2013
- Trial watchOncoImmunology, 2013
- Prognostic Impact of Vitamin B6 Metabolism in Lung CancerCell Reports, 2012
- Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012Cell Death & Differentiation, 2011
- Molecular determinants of immunogenic cell death elicited by anticancer chemotherapyCancer and Metastasis Reviews, 2011
- Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemiaCell Death & Disease, 2010
- Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic DeathCancer Research, 2010
- Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009Cell Death & Differentiation, 2008